Madrigal jumps after Q3 sales for fatty liver drug beats estimates
** Shares of Madrigal Pharmaceuticals MDGL.O rise as much as 17.4% to a two-month high of $253.55
** Stock set for its best day since Dec 2022, if gains hold
** Drugmaker's Q3 rev from its sole product, fatty liver drug Rezdiffra, is $62.2 mln, beating Wall Street estimates of $34.2 mln - LSEG
** Fatty liver disease, known as metabolic dysfunction-associated steatohepatitis (MASH), affects around 5% of the U.S. population. The condition was earlier called non-alcoholic steatohepatitis (NASH)
** "This represents a second consecutive quarter of strong launch execution that increases our conviction in the underlying patient/prescriber demand" - Brokerage Leerink Partners
** MDGL has been able to successfully leverage its first-mover advantage and commercial experience to build the NASH market opportunity - Leerink
** In March, Rezdiffra became the first drug for the condition to be approved by the U.S. FDA
** YTD, stock up 8.1%
Reporting by Puyaan Singh
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
